Scalable Platform for Human Embryonic Stem Cell Differentiation to Cardiomyocytes in Suspended Microcarrier Cultures
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A scalable platform for human embryonic stem cell (hESC)-derived cardiomyocyte (CM) production can provide a readily available source of CMs for cell therapy, drug screening, and cardiotoxicity tests. We have designed and optimized a scalable platform using microcarrier cultures in serum-free media supplemented with SB203580 mitogen-activated protein kinase-inhibitor. Different microcarriers (DE-53, Cytodex-1 and 3, FACT, and TOSOH-10) were used to investigate the effects of type, size, shape, and microcarrier concentrations on the differentiation efficiency. hESCs propagated on TOSOH-10 (protamine derivatized 10-μm beads) at the concentration of 0.125 mg/mL produced 80% beating aggregates, threefold cell expansion, and 20% of CMs (determined by fluorescence-activated cell sorting for myosin heavy chain and α-actinin expression). The ratio of CM/hESC seeded in this system was 0.62 compared to 0.22 in the embryoid body control cultures. The platform robustness has been tested with HES-3 and H1 cell lines, and its scalability was demonstrated in suspended spinner cultures. However, spinner culture yields dropped to 0.33 CM/hESC probably due to shear stress causing some cell death. Cells dissociated from differentiated aggregates showed positive staining for cardio-specific markers such as α-actinin, myosin heavy and light chain, troponin I, desmin, and emilin-2. Finally, CM functionality was also shown by QT-prolongation (QTempo) assay with/without Astemizole. This study represents a new scalable bioprocessing system for CM production using reagents that can comply with Good Manufacturing Practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677 · cited 1×
“7 All these studies reported a partial repair of the infarcted area and an increase in cardiomyocyte (CM) survival and systolic function, and also demonstrated that somatic or adult stem cells cannot be used as source for large-scale CM production since they do not differentiate efficiently into…”
Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389
He, J.-Q., Ma, Y., Lee, Y., Thomson, J. A., & Kamp, T. J. (2003) · Circulation Research · doi:10.1161/01.res.0000080317.92718.99 · Cited by 800
Niebruegge, S., Bauwens, C. L., Peerani, R., Thavandiran, N., Masse, S., Sevaptisidis, E., Nanthakumar, K., Woodhouse, K., Husain, M., Kumacheva, E., et al. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22065 · Cited by 222 · cited 2×
“30 Microcarriers have been recently used for pluripotent hESC propagation in suspended cultures, 31,32 and for differentiation of hESCs to endoderm progeny, 33 but differentiation of hESCs to CMs on microcarriers has not yet been published.”
InfluentialCardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery
Braam, S. R., Passier, R., & Mummery, C. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.001 · Cited by 86
Cited by
Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts
Chong, J. J. H., Yang, X., Don, C. W., Minami, E., Liu, Y.-W., Weyers, J. J., Mahoney, W. M., Van Biber, B., Cook, S. M., Palpant, N. J., et al. (2014) · Nature · doi:10.1038/nature13233 · Cited by 1,408
Physical Cues of Biomaterials Guide Stem Cell Differentiation Fate
Higuchi, A., Ling, Q.-D., Chang, Y., Hsu, S.-T., & Umezawa, A. (2013) · Chemical Reviews · doi:10.1021/cr300426x · Cited by 458
Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics
Chen, K. G., Mallon, B. S., McKay, R. D. G., & Robey, P. G. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2013.12.005 · Cited by 358
“For cardiac differentiation, Lecina et al. reported that hESCs grown on laminin-coated TOSOH-10 in ultra-low attachment plates generatedmore than 80%beating aggregates, or approximately 60% cardiomyocyte conversion related to the initial numbers of seeded hESCs (Lecina et al., 2010).”
BackgroundProcess engineering of human pluripotent stem cells for clinical application
Serra, M., Brito, C., Correia, C., & Alves, P. M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.03.003 · Cited by 303
Chen, A. K.-L., Reuveny, S., & Oh, S. K. W. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.03.006 · Cited by 292
Self-citation
Metadata
- Authors
- Lecina, M., Ting, S., Choo, A., Reuveny, S., & Oh, S.
- Venue
- Tissue Engineering Part C: Methods
- Publisher
- SAGE Publications
- Published
- 2010-12
- Volume
- 16
- Issue
- 6
- Pages
- 1609-1619
- ISSN
- 1937-3384 (ISSN-L)
- 1937-3392
- OpenAlex
- W2014664388
- Cited by
- 123
- References
- 5
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Scalable Platform for Human Embryonic Stem Cell Differentiation to Cardiomyocytes in Suspended Microcarrier Cultures. https://app.cochat.ai/papers/10.1089/ten.tec.2010.0104
- The paper
- Lecina, M., Ting, S., Choo, A., Reuveny, S., & Oh, S. (2010). Scalable Platform for Human Embryonic Stem Cell Differentiation to Cardiomyocytes in Suspended Microcarrier Cultures. Tissue Engineering Part C: Methods. https://doi.org/10.1089/ten.tec.2010.0104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.